Abstract
Background
According to the current guidelines of the European Society of Cardiology, patients with left-sided infective endocarditis are treated with intravenous antibiotics for 4–6 weeks, leading to extensive hospital stay and high costs. Recently, the Partial Oral Treatment of Endocarditis (POET) trial suggested that partial oral treatment is effective and safe in selected patients. Here, we investigated if such patients are seen in our daily clinical practice.
Methods
We enrolled 119 adult patients diagnosed with left-sided infective endocarditis in a retrospective, observational study. We identified those that would be eligible for switching to partial oral antibiotic treatment as defined in the POET trial (e.g. stable clinical condition without signs of infection). Secondary objectives were to provide insight into the time until each patient was eligible for partial oral treatment, and to determine parameters of longer hospital stay and/or need for extended intravenous antibiotic treatment.
Results
Applying the POET selection criteria, the condition of 38 patients (32%) was stable enough to switch them to partial oral treatment, of which 18 (47.3%), 8 (21.1%), 9 (23.7%) and 3 patients (7.9%) were eligible for switching after 10, 14, 21 days or 28 days of intravenous treatment, respectively.
Conclusion
One-third of patients who presented with left-sided endocarditis in routine clinical practice were possible candidates for switching to partial oral treatment. This could have major implications for both the patient’s quality of life and healthcare costs. These results offer an interesting perspective for implementation of such a strategy, which should be accompanied by a prospective cost-effectiveness analysis.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details
1 University Medical Center Utrecht, Department of Cardiology, Utrecht, The Netherlands (GRID:grid.7692.a) (ISNI:0000000090126352)
2 University Medical Center Utrecht, Department of Cardiothoracic Surgery, Utrecht, The Netherlands (GRID:grid.7692.a) (ISNI:0000000090126352)
3 University Medical Center Utrecht, Department of Microbiology, Utrecht, The Netherlands (GRID:grid.7692.a) (ISNI:0000000090126352)
4 University Medical Center Utrecht, Department of Internal Medicine and Infection Diseases, Utrecht, The Netherlands (GRID:grid.7692.a) (ISNI:0000000090126352)
5 Haga Hospital, Department of Cardiology, The Hague, The Netherlands (GRID:grid.413591.b) (ISNI:0000 0004 0568 6689)
6 Amsterdam University Medical Center, AMC/University of Amsterdam, Department of Cardiology, Amsterdam, The Netherlands (GRID:grid.7177.6) (ISNI:0000000084992262)





